Exploratory analyses
PD, PD‐L1
DISEASE
Eighteen patients received different regimens after dropout. Eight patients received the original regimen (toripalimab plus anlotinib) in combination with pemetrexed, four patients used pemetrexed and carboplatin in combination with bevacizumab, and one patient used pemetrexed and bevacizumab plus sintilimab; the remaining patients' regimens are shown in the Table Progression‐free survival curves for patients with different treatment. (A) Progression‐free survival curves 2 for patients with bevacizumab, carboplatin, pemetrexed or toripalimab, anlotinib, and pemetrexed. (B) Progression‐free survival curves 2 for patients with or without platinum.Of the 206 mutations detected in the patients' peripheral blood samples, Relationship between baseline Relationship between baseline blood soluble PD‐L1 concentration and efficacy. (A) blood soluble PD‐L1 expression at baseline in different group; PD, progressive disease; SD, stable disease; (B) Progression‐free survival curves for patients with high level or low level of blood soluble PD‐L1 expression at baseline; PD‐L1‐H, high level of blood soluble PD‐L1 expression at baseline; PD‐L1‐L, low level of blood soluble PD‐L1 expression at baseline.